Financial Instruments And Risk Management (Tables)

9 Months Ended

Sep. 30, 2011

Financial Instruments And Risk Management

Derivatives Designated As Hedging Instruments Fair Values Of Derivative Instruments

	Asset Derivatives
	September 30, 2011			December 31, 2010
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
(In thousands)
Interest rate swaps	Prepaid expenses and other current assets	$	39,780	Prepaid expenses and other current assets	$	—
Foreign currency forward contracts	Prepaid expenses and other current assets		—	Prepaid expenses and other current assets		8,884
Total		$	39,780		$	8,884
	Liability Derivatives
	September 30, 2011			December 31, 2010
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
(In thousands)
Interest rate swaps	Other current liabilities	$	17,340	Other current liabilities	$	25,666
Foreign currency forward contracts	Other current liabilities		16,975	Other current liabilities		—
Foreign currency borrowings	Long-term debt		914,281	Long-term debt		909,255
Total		$	948,596		$	934,921

Derivatives Not Designated As Hedging Instruments Fair Values Of Derivative Instruments

	Asset Derivatives
	September 30, 2011			December 31, 2010
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
(In thousands)
Foreign currency forward contracts	Prepaid expenses and other current assets	$	3,252	Prepaid expenses and other current assets	$	2,668
Purchased cash convertible note hedge	Other assets		294,900	Other assets		472,400
Total		$	298,152		$	475,068
	Liability Derivatives
	September 30, 2011			December 31, 2010
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
(In thousands)
Foreign currency forward contracts	Other current liabilities	$	8,810	Other current liabilities	$	7,375
Cash conversion feature of Cash Convertible Notes	Long-term debt		294,900	Long-term debt		472,400
Total		$	303,710		$	479,775

Effect Of Derivative Instruments On Condensed Consolidated Statements Of Operations Derivatives In Fair Value Hedging Relationships

	Location of Gain or (Loss) Recognized in Earnings on Derivatives	Amount of Gain or (Loss) Recognized in Earnings on Derivatives
		Three Months Ended September 30,				Nine Months Ended September 30,
		2011		2010		2011		2010
(In thousands)
Interest Rate Swaps	Interest Expense	$	34,985	$	—	$	39,780	$	—
Total		$	34,985	$	—	$	39,780	$	—

	Location of Gain or (Loss) Recognized in Earnings on Hedged Items	Amount of Gain or (Loss) Recognized in Earnings on Hedged Items
		Three Months Ended September 30,					Nine Months Ended September 30,
		2011			2010		2011			2010
(In thousands)
2018 Senior Notes	Interest Expense	$	(34,985	)	$	—	$	(39,780	)	$	—
Total		$	(34,985	)	$	—	$	(39,780	)	$	—

Effect Of Derivative Instruments On The Condensed Consolidated Statements Of Operations Derivatives In Cash Flow Hedging Relationships

		Amount of Gain or (Loss) Recognized in AOCE (Net of Tax) on Derivative (Effective Portion)
		Three Months Ended September 30,						Nine Months Ended September 30,
		2011			2010			2011			2010
(In thousands)
Foreign currency forward contracts		$	(30,105	)	$	9,293		$	(28,417	)	$	6,430
Interest rate swaps			2,354			7,440			5,243			10,481
Total		$	(27,751	)	$	16,733		$	(23,174	)	$	16,911
	Location of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion)	Amount of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion)
		Three Months Ended September 30,						Nine Months Ended September 30,
		2011			2010			2011			2010
(In thousands)
Foreign currency forward contracts	Net revenues	$	(267	)	$	(232	)	$	2,099		$	647
Interest rate swaps	Interest expense		(466	)		(5,843	)		(2,655	)		(28,201	)
Total		$	(733	)	$	(6,075	)	$	(556	)	$	(27,554	)
	Location of Gain or (Loss) Excluded from the Assessment of Hedge Effectiveness	Amount of Gain or (Loss) Excluded from the Assessment of Hedge Effectiveness
		Three Months Ended September 30,						Nine Months Ended September 30,
		2011			2010			2011			2010
(In thousands)
Foreign currency forward contracts	Other income (expense), net	$	12,158		$	(4,971	)	$	17,246		$	(3,721	)
Total		$	12,158		$	(4,971	)	$	17,246		$	(3,721	)

Effect Of Derivative Instruments On The Condensed Consolidated Statement Of Operations Derivatives In Net Investment Hedging Relationships

	Amount of Gain or (Loss) Recognized in AOCE (Net of Tax) on Derivative (Effective Portion)
	Three Months Ended September 30,					Nine Months Ended September 30,
	2011		2010			2011			2010
(In thousands)
Foreign currency borrowings	$	7,428	$	(58,079	)	$	(39,868	)	$	30,979
Total	$	7,428	$	(58,079	)	$	(39,868	)	$	30,979

Effect Of Derivative Instruments On The Condensed Consolidated Statement Of Operations Derivatives Not Designated As Hedging Instruments

	Location of Gain or (Loss) Recognizedin Earnings on Derivatives	Amount of Gain or (Loss) Recognized in Earnings on Derivatives
		Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)		2011			2010			2011			2010
Foreign currency forward contracts	Other income (expense), net	$	(19,368	)	$	(4,590	)	$	(5,244	)	$	(27,741	)
Cash conversion feature of Cash Convertible Notes	Other income (expense), net		286,500			(43,200	)		177,500			19,500
Purchased cash convertible note hedge	Other income (expense), net		(286,500	)		43,200			(177,500	)		(19,500	)
Total		$	(19,368	)	$	(4,590	)	$	(5,244	)	$	(27,741	)

Financial Assets And Liabilities Carried At Fair Value

	September 30, 2011
	Level 1		Level 2		Total
	(In thousands)
Financial Assets:
Trading securities:
Equity securities — exchange traded funds	$	6,135	$	—	$	6,135
Total trading securities		6,135		—		6,135
Available-for-sale fixed income investments:
U.S. Treasuries		—		12,899		12,899
Corporate bonds		—		6,761		6,761
Agency mortgage-backed securities		—		1,652		1,652
Other		—		2,646		2,646
Total available-for-sale fixed income investments		—		23,958		23,958
Available-for-sale equity securities:
Biosciences industry		156		—		156
Total available-for-sale equity securities		156		—		156
Foreign exchange derivative assets		—		3,252		3,252
Interest rate swap derivative assets		—		39,780		39,780
Purchased cash convertible note hedge		—		294,900		294,900
Total assets at fair value (1) (2)	$	6,291	$	361,890	$	368,181
Financial Liabilities:
Foreign exchange derivative liabilities	$	—	$	25,785	$	25,785
Interest rate swap derivative liabilities		—		17,340		17,340
Cash conversion feature of cash convertible notes		—		294,900		294,900
Total liabilities at fair value (1) (2)	$	—	$	338,025	$	338,025

	December 31, 2010
	Level 1		Level 2		Total
	(In thousands)
Financial Assets:
Trading securities:
Equity securities — exchange traded funds	$	3,693	$	—	$	3,693
Total trading securities		3,693		—		3,693
Available-for-sale fixed income investments:
U.S. Treasuries		—		12,387		12,387
Corporate bonds		—		8,116		8,116
Agency mortgage-backed securities		—		1,934		1,934
Other		—		2,573		2,573
Total available-for-sale fixed income investments		—		25,010		25,010
Available-for-sale equity securities:
Biosciences industry		382		—		382
Total available-for-sale equity securities		382		—		382
Foreign exchange derivative assets		—		19,877		19,877
Purchased cash convertible note hedge		—		472,400		472,400
Total assets at fair value (1) (2)	$	4,075	$	517,287	$	521,362
Financial Liabilities:
Foreign exchange derivative liabilities	$	—	$	7,729	$	7,729
Interest rate swap derivative liabilities		—		25,666		25,666
Cash conversion feature of cash convertible notes		—		472,400		472,400
Total liabilities at fair value (1) (2)	$	—	$	505,795	$	505,795

⁽¹⁾  The Company chose not to elect the fair value option for its financial assets and liabilities that had not been previously carried at fair value. Therefore, material financial assets and liabilities not carried at fair value, such as short-term and long-term debt obligations and trade accounts receivable and payable, are still reported at their carrying values.

⁽²⁾  None of the Company's financial assets and liabilities measured at fair value on a recurring basis are valued using Level 3 inputs as of September 30, 2011 or December 31, 2010.